PACS 📈 PACS Group - Overview

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock •

PACS: Nursing Homes, Assisted Living Facilities, Senior Care Services

PACS Group, Inc. is a multifaceted healthcare company that operates a diverse portfolio of skilled nursing facilities, assisted living facilities, and independent living facilities across the United States. Through its subsidiaries, the company delivers a range of senior care services, catering to the unique needs of its residents. This includes providing medical care, rehabilitation services, and support with daily activities, all within a safe and comfortable environment. By offering a continuum of care, PACS Group, Inc. enables seniors to age in place, transitioning seamlessly between different levels of care as their needs evolve.

In addition to its operational capabilities, PACS Group, Inc. is also engaged in the acquisition, ownership, and leasing of healthcare-related properties. This strategic approach allows the company to expand its footprint, enhance its service offerings, and drive growth through strategic investments. With a focus on delivering high-quality care and exceptional patient experiences, PACS Group, Inc. has established itself as a reputable player in the healthcare industry. Founded in 2013 and headquartered in Farmington, Utah, the company has built a strong foundation for long-term success, with its common stock listed on the New York Stock Exchange (NYSE) under the ticker symbol PACS.

As a specialized healthcare company, PACS Group, Inc. operates within the Health Care Facilities sub-industry, as classified by the Global Industry Classification Standard (GICS). This sub-industry encompasses a range of companies that provide medical and healthcare services, including hospitals, nursing homes, and assisted living facilities. By focusing on the senior care segment, PACS Group, Inc. is well-positioned to capitalize on the growing demand for age-related healthcare services, driven by the aging population and increasing life expectancy. For more information about the company, its services, and its investment opportunities, visitors can access the PACS Group, Inc. website at https://pacs.com.

Additional Sources for PACS Stock

PACS Stock Overview

Market Cap in USD 6,319m
Sector Healthcare
Industry Medical Care Facilities
GiC Sub-Industry Health Care Facilities
IPO / Inception 2024-04-11

PACS Stock Ratings

Growth 5y -53.9%
Fundamental 42.0%
Dividend -
Rel. Strength Industry -3037
Analysts 4.67/5
Fair Price Momentum 11.95 USD
Fair Price DCF 18.15 USD

PACS Dividends

No Dividends Paid

PACS Growth Ratios

Growth Correlation 3m -81.9%
Growth Correlation 12m 5.6%
Growth Correlation 5y 5.6%
CAGR 5y -43.43%
CAGR/Mean DD 5y -3.22
Sharpe Ratio 12m -0.61
Alpha -46.30
Beta -0.08
Volatility 103.07%
Current Volume 1202.6k
Average Volume 20d 1111k
What is the price of PACS stocks?
As of December 21, 2024, the stock is trading at USD 13.01 with a total of 1,202,600 shares traded.
Over the past week, the price has changed by -15.57%, over one month by -24.58%, over three months by -68.09% and over the past year by -43.43%.
Is PACS Group a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, PACS Group (NYSE:PACS) is currently (December 2024) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 42.02 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PACS as of December 2024 is 11.95. This means that PACS is currently overvalued and has a potential downside of -8.15%.
Is PACS a buy, sell or hold?
PACS Group has received a consensus analysts rating of 4.67. Therefor, it is recommend to buy PACS.
  • Strong Buy: 4
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecast for PACS stock price target?
According to ValueRays Forecast Model, PACS PACS Group will be worth about 12.9 in December 2025. The stock is currently trading at 13.01. This means that the stock has a potential downside of -0.77%.
Issuer Forecast Upside
Wallstreet Target Price 41 215.1%
Analysts Target Price 41 215.1%
ValueRay Target Price 12.9 -0.8%